We are live on
!
Find out more
IC
Ikarian Capital Portfolio holdings
AUM
$1.23B
1-Year Est. Return
600.17%
This Fund
S&P 500
This Quarter
Est. Return
+69.49%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$617M
AUM Growth
–
Cap. Flow
+$516M
Cap. Flow
% of AUM
83.64%
Top 10 Holdings %
Top 10 Hldgs %
46.54%
Holding
114
New
114
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SAGE
Sage Therapeutics
SAGE
|
+$16.4M |
| 2 |
CHMA
Chiasma, Inc. Common Stock
CHMA
|
+$5.74M |
| 3 |
Immunovant
IMVT
|
+$5.65M |
| 4 |
Aurinia Pharmaceuticals
AUPH
|
+$4.43M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
+$4.34M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
PUT
Assembly Biosciences
ASMB
$507M
| $3.07M | 0.5% |
+12,500
| New | +$2.3M |
|
|
ARQL
52
DELISTED
Arqule Inc
ARQL
| $2.97M | 0.48% |
+148,930
| New | +$1.73M |
|
53
PUT
Axsome Therapeutics
AXSM
$12.1B
| $2.88M | 0.47% |
+27,900
| New | +$1.13M |
|
54
Avalo Therapeutics
AVTX
$1.04B
| $2.8M | 0.45% |
+180
| New | +$1.9M |
|
55
PUT
CEL-SCI Corp
CVM
$21M
| $2.75M | 0.45% |
+10,007
| New | +$2.36M |
|
56
Puma Biotechnology
PBYI
$406M
| $2.72M | 0.44% |
+311,253
| New | +$2.58M |
|
57
PUT
Wave Life Sciences
WVE
$1.12B
| $2.4M | 0.39% |
+300,000
| New | +$7.35M |
|
58
CALL
Agios Pharmaceuticals
AGIO
$2.16B
| $2.39M | 0.39% |
+50,000
| New | +$1.89M |
|
59
AnaptysBio
ANAB
$1.54B
| $2.32M | 0.38% |
+143,000
| New | +$3.38M |
|
60
BioXcel Therapeutics
BTAI
$26.1M
| $2.31M | 0.37% |
+9,898
| New | +$995K |
|
61
Ocular Therapeutix
OCUL
$1.88B
| $2.2M | 0.36% |
+557,659
| New | +$1.94M |
|
|
KDNY
62
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $2.17M | 0.35% |
+367,706
| New | +$2M |
|
63
Ultragenyx Pharmaceutical
RARE
$2.54B
| $2.14M | 0.35% |
+50,000
| New | +$2.06M |
|
|
CCXI
64
DELISTED
ChemoCentryx, Inc.
CCXI
| $1.84M | 0.3% |
+46,423
| New | +$815K |
|
|
MNK
65
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $1.79M | 0.29% |
+512,000
| New | +$1.6M |
|
66
CALL
MacroGenics
MGNX
$245M
| $1.63M | 0.26% |
+150,000
| New | +$1.48M |
|
67
CALL
Coherus Oncology
CHRS
$222M
| $1.51M | 0.25% |
+84,100
| New | +$1.55M |
|
68
CALL
Insmed
INSM
$22.5B
| $1.46M | 0.24% |
+61,200
| New | +$1.24M |
|
69
CALL
KALA BIO
KALA
$12.6M
| $1.46M | 0.24% |
+158
| New | +$1.53M |
|
70
Ovid Therapeutics
OVID
$439M
| $1.45M | 0.24% |
+350,000
| New | +$1.11M |
|
71
InflaRx
IFRX
$256M
| $1.42M | 0.23% |
+359,128
| New | +$1.05M |
|
72
CALL
Solid Biosciences
SLDB
$784M
| $1.36M | 0.22% |
+20,373
| New | +$2.25M |
|
|
AIMT
73
DELISTED
Aimmune Therapeutics
AIMT
| $1.34M | 0.22% |
+40,000
| New | +$1.12M |
|
74
Mustang Bio
MBIO
$4.78M
| $1.32M | 0.21% |
+431
| New | +$987K |
|
75
CALL
Viking Therapeutics
VKTX
$3.93B
| $1.2M | 0.19% |
+150,000
| New | +$1.09M |
|
Similar funds
FLII
NHAS
HCA
GX
WCM
MP
IA
IB
Ikarian Capital's Q4 2019 Portfolio in Review
Q4 2019 is the first quarter with a 13F filing on record for Ikarian Capital, which disclosed 114 positions worth $617M. Its ten largest holdings account for 47% of the portfolio.
Its largest position is Sage Therapeutics: 133,000 shares worth $9.6M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets.
- Ikarian Capital's largest Q4 2019 buy was Sage Therapeutics: 133,000 shares worth $9.6M.
- Ikarian Capital's ten largest holdings make up 47% of its $617M portfolio in Q4 2019.
- Ikarian Capital disclosed 114 positions in Q4 2019, its first 13F filing on record.
Based on Ikarian Capital's 13F filing for Q4 2019, filed 31 Jan 2020.